AKT2 and metabolic disease: The study found that BCAAs are associated with obesity-related metabolic disorders, BCAAs aggravate obesity-related hepatic glucolipid metabolism disorders by weakening AKT2 signaling pathway and supplementing BCAAs significantly increased hepatic gluconeogenesis in high-fat diet-induced obese mice and inhibited hepatic lipogenesis.